A Higher Strength Of Cholesterol-Lowering Drugs Did Not Increase The Risk Of Kidney Injury After Heart Attack
A higher strength of cholesterol-lowering drugs, or statins, did not increase the risk of kidney injury among heart attack survivors, according to preliminary research presented at the American Heart Association’s Emerging Science Series Webinar.*
Statins have been shown to reduce the risk of a first or recurrent heart attack, but recent observational studies suggest that high doses may be linked to a higher incidence of kidney injury.
In this study, researchers analyzed data from two large clinical trials in which survivors were randomly assigned to receive either high- or low-dose statins. Higher strenght statins did not increase the risk of hospitalizations with kidney injury when compared to low-dose statins. In addition, concentrations of a blood protein, called creatinine, which reflects kidney function were comparable between the two groups during follow-up.
“These findings provide important reassurance to clinicians that the use of some high-potency statins will not increase the risk of kidney injury,” said Amy Sarma, M.D., M.H.S., the study’s lead author and a resident physician in internal medicine at Brigham and Women’s Hospital in Boston, Mass.
The study data were obtained from two trials with more than 4,000 participants each – the PROVE IT-TIMI 22, and the A-to-Z Trial.
Co-authors are Christopher P. Cannon, M.D.; Stephen D. Wiviott, M.D.; Marc S. Sabatine, M.D., M.P.H.; Marc A. Pfeffer, M.D., Ph.D.; Elaine B. Hoffman. Ph.D.; Jianping Guo, M.A.S. and James A. de Lemos, M.D. The senior author was Michelle L. O’Donoghue, M.D., M.P.H.
Author disclosures are on the abstract. Bristol-Myers Squibb and Sankyo funded the PROVE IT-TIMI 22 study. Merck funded the A-to-Z trial.
View the webinar at http://www.scientificsessions.org/emergingscience.